drugset / Trial / NCT04726345

Effect of Antihistamines on Ureteral Stent-Related Symptoms

NCT04726345

Phase 2 Completed 78 enrolled Columbia University Coloplast A/S · collab
RandomizedParallel-groupDouble-blindSupportive care

Summary

This is a prospective, double-blind, randomized, open-label, single-center trial of up to 78 participants who are adult patients (aged 18-80 years) and are undergoing unilateral retrograde ureteroscopy with planned ureteral stent placement for treatment of urinary tract stones. Eligible patients will be randomly and divided into two groups in a 1:1 ratio. Group A will receive fexofenadine 180 mg once daily in addition to standard of care treatment. Group B will receive placebo in addition to standard of care treatment. The routine standard of care treatment will consist of oral non-steroidal anti-inflammatory drugs (NSAIDs). The primary outcomes of the study are the Ureteral Stent Symptom Questionnaire (USSQ) urinary symptom score and pain score. Secondary outcomes include (i) number of office phone calls due to urinary symptoms; (ii) duration of analgesic use; (iii) duration and quantity of narcotic use; (iv) number of emergency department visits; (v) drug-related adverse effects; (vi) other domains of the USSQ.

Timeline

Start
2021-06-29
Primary completion
2024-06-30
Completion
2024-06-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Fexofenadine Unknown 180 mg Oral

Indications